{"gene":"NR1I3","run_date":"2026-04-29T11:37:57","timeline":{"discoveries":[{"year":1994,"finding":"NR1I3 (MB67) was identified as an orphan nuclear hormone receptor predominantly expressed in liver that binds and transactivates retinoic acid response elements (DR5 motifs) as a heterodimer with RXR, exhibiting constitutive (ligand-independent) transactivation activity dependent on the AF-2 motif.","method":"Receptor cloning, gel shift assays, transient transfection/reporter assays, RXR heterodimerization studies","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 — original cloning with multiple orthogonal functional assays; foundational paper replicated by subsequent work","pmids":["8114692"],"is_preprint":false},{"year":1997,"finding":"NR1I3 (hCAR/mCAR) acts as a constitutive transcriptional activator that heterodimerizes with RXR to bind retinoic acid response elements; a truncated splice variant mCAR2 lacking part of the ligand-binding/dimerization domain fails to bind DNA or transactivate, and also cannot inhibit mCAR1/hCAR activity.","method":"Gene cloning, transient transfection reporter assays, gel shift/DNA binding assays, dominant-negative analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods in original discovery paper, replicated across labs","pmids":["9295294"],"is_preprint":false},{"year":1998,"finding":"CAR-beta (NR1I3) constitutive transcriptional activity results from ligand-independent recruitment of transcriptional co-activators; androstanol and androstenol (3α-hydroxy, 5α-reduced androstanes) function as inverse agonists by promoting co-activator release from the ligand-binding domain without affecting heterodimerization or DNA binding, defining a class of naturally occurring nuclear receptor inverse agonists.","method":"In vitro transcription/reporter assays, ligand-binding studies, co-activator interaction assays, steroid structure-activity analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — reconstitution of co-activator recruitment/release mechanism with stereospecificity analysis; published in Nature and widely replicated","pmids":["9783588"],"is_preprint":false},{"year":2000,"finding":"CAR (NR1I3) can activate CYP3A genes through PXR/SXR response elements, and conversely PXR/SXR can activate CYP2B genes through the phenobarbital response element (PBRE), demonstrating cross-regulatory overlap between these two xenobiotic receptors in regulating multiple CYP gene classes.","method":"Cell-based reporter assays, transgenic mouse studies, gene expression analysis","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 — genetic (transgenic) and biochemical evidence from multiple CYP gene promoters; replicated in vivo","pmids":["11114890"],"is_preprint":false},{"year":2002,"finding":"CAR (NR1I3) regulates acetaminophen metabolism and hepatotoxicity by inducing expression of three acetaminophen-metabolizing enzymes (including CYP enzymes); CAR null mice are resistant to acetaminophen toxicity, and administration of the inverse agonist androstanol 1 hour after acetaminophen treatment blocked hepatotoxicity in wild-type but not CAR null mice.","method":"CAR knockout mouse studies, gene expression analysis, in vivo hepatotoxicity model, pharmacological inverse agonist administration","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout with pharmacological rescue, published in Science; defines CAR as a key regulator of acetaminophen metabolism","pmids":["12376703"],"is_preprint":false},{"year":2002,"finding":"CAR (NR1I3) transcriptionally activates CYP3A4 through two high-affinity binding motifs located ~7720 and ~150 bp upstream of the transcription start site, requiring cooperativity between the proximal promoter and the distal xenobiotic-responsive enhancer module (XREM); these CAR response elements also mediate transactivation by PXR.","method":"Transient transfection reporter assays, gel shift assays, in vitro and in vivo CAR activation, primary human hepatocyte studies","journal":"Molecular pharmacology","confidence":"High","confidence_rationale":"Tier 1-2 — promoter mapping with gel shifts and reporter assays plus in vivo validation; widely replicated","pmids":["12130689"],"is_preprint":false},{"year":2002,"finding":"CAR (NR1I3) constitutively regulates CYP2C9 expression through a newly identified distal CAR-responsive enhancer (CAR-RE) located between -2900 and -2841 bp of the CYP2C9 promoter, containing two DR-5 nuclear receptor binding motifs that bind hCAR, mCAR, and human PXR.","method":"Transfection assays, gel shift assays, mRNA quantification in HepG2 cells","journal":"Molecular pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — gel shift and reporter assays identify specific binding motifs; single lab study","pmids":["12181452"],"is_preprint":false},{"year":2003,"finding":"CITCO was identified as the first selective human CAR agonist; it potently activates CAR (NR1I3) in a fluorescence-based assay, is selective over PXR and other nuclear receptors, induces CAR nuclear translocation, and induces the prototypical CAR target gene CYP2B6 in primary human hepatocytes. Using CITCO, CAR and PXR activators were shown to differentially regulate overlapping but distinct sets of drug-metabolizing enzyme genes.","method":"Fluorescence-based receptor activation assay, nuclear translocation assay, primary human hepatocyte gene expression profiling, selectivity panel against other nuclear receptors","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal assays identifying first selective human CAR agonist; foundational tool paper with broad use","pmids":["12611900"],"is_preprint":false},{"year":2003,"finding":"CAR (NR1I3) activates all five components of the bilirubin-clearance pathway in liver; this induction is absent in CAR null mice, is present in mice expressing human CAR, and CAR null mice are defective in clearing chronically elevated bilirubin. Bilirubin itself can directly activate CAR. CAR expression is very low in neonatal liver, suggesting its functional deficit contributes to neonatal jaundice.","method":"CAR knockout and humanized mouse models, gene expression analysis, bilirubin clearance assays, receptor activation assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout and humanized mouse models with functional bilirubin clearance readout; replicated findings","pmids":["12644704"],"is_preprint":false},{"year":2003,"finding":"PXR and CAR (NR1I3) both induce specific UGT1A isoforms involved in estrogen, thyroxin, bilirubin, and carcinogen metabolism; transgenic mice expressing constitutively active human PXR show markedly increased UGT activity and steroid clearance, demonstrating that both receptors transduce phase I and phase II adaptive hepatic responses.","method":"Transgenic mouse studies, UGT activity assays, gene expression analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — in vivo transgenic model with enzymatic activity measurements; defines phase I and II regulatory role","pmids":["12644700"],"is_preprint":false},{"year":2003,"finding":"Functional and structural comparison of PXR (NR1I2) and CAR (NR1I3) reveals key differences in gene expression targets, ligand profiles in cell-based assays, and crystallographic/structural features, highlighting their distinct but overlapping physiological roles as xenosensors.","method":"Gene expression assays, cell-based ligand profiling, crystallographic and structural modeling analyses","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 1-2 — structural and functional comparison with crystallography; single comparative study","pmids":["12573482"],"is_preprint":false},{"year":2004,"finding":"The X-ray crystal structure of the human CAR (NR1I3)/RXRα heterodimer reveals that CAR contains a unique single-turn Helix X that restricts conformational freedom of the C-terminal AF2 helix, favoring the active (transcriptionally competent) state without ligand. Helix X and AF2 sit atop four amino acids shielding the CAR ligand-binding pocket. A fatty acid ligand was found in the RXRα binding pocket, and stabilizing interactions from the heterodimer interface hold RXRα in an active conformation, explaining ligand-independent constitutive activation.","method":"X-ray crystallography of CAR/RXRα heterodimer, structural analysis of ligand-binding pocket","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 — crystal structure providing direct mechanistic basis for constitutive activity; foundational structural paper","pmids":["15610735"],"is_preprint":false},{"year":2004,"finding":"CAR (NR1I3) and PXR both bind to an ER6 motif in the CYP3A5 promoter and transactivate CYP3A5 expression; rifampin induces CYP3A5 mRNA in human hepatocytes and intestinal biopsies via this mechanism, and hepatic PXR expression correlates with CYP3A5 mRNA levels.","method":"Reporter assays, gel shift/EMSA, RT-PCR in primary hepatocytes and intestinal biopsies, correlation analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — multiple methods including primary human tissue; single study","pmids":["15252010"],"is_preprint":false},{"year":2005,"finding":"The human CAR splice variant CAR3 (NR1I3), which has a 5-amino acid insertion in the ligand-binding domain, is ligand-activated (not constitutively active); CITCO and clotrimazole act as activating ligands for CAR3 (clotrimazole is an inverse agonist for the reference CAR1). Transactivation by CAR3 requires its DNA-binding domain and AF-2 motif, is markedly enhanced by RXRα cotransfection through an RXR AF-2-dependent mechanism, and RXR augments CAR3 activity by facilitating coactivator (SRC-1) recruitment.","method":"Transient transfection reporter assays, mammalian two-hybrid assays, mutational analysis of AF-2 and DNA-binding domains, RXR cotransfection studies","journal":"Molecular pharmacology","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including two-hybrid coactivator recruitment assay and domain mutagenesis","pmids":["16099843"],"is_preprint":false},{"year":2005,"finding":"Chronic activation of CAR (NR1I3) causes hepatocarcinogenesis; CAR null mice are completely resistant to tumorigenic effects of chronic xenobiotic stress. In the acute xenobiotic response, CAR directly up-regulates Mdm2 expression, contributing to increased DNA replication and inhibition of p53-mediated apoptosis, linking chronic environmental stress to tumor formation via this specific molecular mechanism.","method":"CAR knockout mouse carcinogenesis model, acute xenobiotic stress experiments, Mdm2 expression analysis, apoptosis and DNA replication assays","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout with identified molecular mechanism (Mdm2/p53 pathway); replicated findings","pmids":["15831521"],"is_preprint":false},{"year":2005,"finding":"CAR (NR1I3) and PXR regulate CYP2C8 expression through a distal PXR/CAR-binding site in the CYP2C8 promoter; CITCO (CAR agonist) and rifampicin (PXR agonist) induce CYP2C8 through this site. Additional regulatory elements for glucocorticoid receptor (GR) and HNF4α were also identified in the CYP2C8 promoter.","method":"Reporter assays, gel shift assays, primary human hepatocyte induction studies","journal":"Molecular pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — promoter mapping with functional validation in primary hepatocytes; single study","pmids":["15933212"],"is_preprint":false},{"year":2004,"finding":"IL-1β inhibits CAR (NR1I3) expression and CAR-mediated induction of drug-metabolizing genes (CYP2B6, CYP2C9, CYP3A4, UGT1A1, GSTA1, GSTA2, SLC21A6) in human hepatocytes via NF-κB p65 activation, which interferes with glucocorticoid receptor (GR)-mediated transactivation of the CAR promoter through its distal glucocorticoid response element; LPS and IL-1β inhibit dexamethasone-induced histone H4 acetylation at the proximal CAR promoter region, as shown by chromatin immunoprecipitation.","method":"Human hepatocyte culture, RT-PCR, transient transfection assays, chromatin immunoprecipitation (ChIP), NF-κB inhibitor and overexpression studies","journal":"Hepatology","confidence":"High","confidence_rationale":"Tier 1-2 — ChIP plus multiple functional assays demonstrating inflammatory suppression of CAR via NF-κB/GRE chromatin mechanism","pmids":["15382119"],"is_preprint":false},{"year":2008,"finding":"CAR (NR1I3) regulates serum triglyceride levels under metabolic stress; ob/ob mice crossed onto Car−/− background show completely normalized serum triglycerides, and Car−/− mice are protected from high-fat diet-induced hypertriglyceridemia. Pharmacological CAR activation with TCPOBOP increases serum triglycerides in a CAR-dependent manner. CAR activation suppresses PPARα expression and its target genes (Cyp4a14, CPT1α, CTE), and Car−/− animals exhibit increased hepatic fatty acid oxidation, indicating that CAR antagonizes PPARα-mediated fatty acid oxidation.","method":"Car knockout and ob/ob mouse genetic crosses, high-fat diet model, pharmacological CAR activation (TCPOBOP), PPARα target gene expression analysis, fatty acid oxidation assays","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic mouse models with pharmacological validation; identifies PPARα as downstream effector","pmids":["18941143"],"is_preprint":false},{"year":2008,"finding":"CAR (NR1I3) and PXR cross-talk with multiple hormone-responsive transcription factors (FoxO1, FoxA2, CREB, PGC-1α) to downregulate hepatic energy metabolism including gluconeogenesis, fatty acid oxidation, and ketogenesis while upregulating lipogenesis; CAR also modulates thyroid hormone activity by regulating type 1 deiodinase in the regenerating liver.","method":"Gene expression studies, nuclear receptor cross-talk assays, hepatic metabolic pathway analysis in rodent models","journal":"Drug metabolism and pharmacokinetics","confidence":"Medium","confidence_rationale":"Tier 3 — review synthesizing primary data; cross-talk mechanisms identified in multiple primary studies but summarized here","pmids":["18305370"],"is_preprint":false},{"year":2009,"finding":"Retinoids (including all-trans retinoic acid and 9-cis retinoic acid) activate the RXRα/CAR (NR1I3)-mediated pathway and induce CYP3A gene expression; RXRα and CAR are recruited to both the proximal ER6 and distal XREM nuclear receptor response elements of the CYP3A4 gene promoter, as demonstrated by chromatin immunoprecipitation assay. Induction is preferentially mediated by RXRα/CAR and RXRγ/CAR heterodimers.","method":"Transient transfection assays in HepG2 cells, chromatin immunoprecipitation (ChIP), RT-PCR","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP with functional reporter assays; single lab study","pmids":["19686701"],"is_preprint":false},{"year":2013,"finding":"NR1I3 gene polymorphisms are significantly associated with tacrolimus pharmacokinetics (dose-adjusted trough concentration) in liver transplant patients, indicating that NR1I3 variants influence tacrolimus metabolism in vivo in humans.","method":"Pharmacokinetic analysis in 96 liver transplant patients, genotyping of NR1I3 and CYP3A5 polymorphisms, multiple linear regression modeling","journal":"Drug metabolism and pharmacokinetics","confidence":"Low","confidence_rationale":"Tier 3-4 — clinical association study; no direct mechanistic experiment linking specific NR1I3 variant to altered gene expression or enzyme activity","pmids":["24351870"],"is_preprint":false},{"year":2014,"finding":"CAR (NR1I3) can be activated by both direct ligand binding and ligand-independent (indirect) mechanisms; without activation, CAR forms a cytoplasmic protein complex. Indirect activation involves nuclear translocation through multiple signaling pathways including those affecting the cytoplasmic retention complex, while direct activation involves ligand binding followed by nuclear translocation. Both modes of activation converge on nuclear accumulation and target gene transactivation.","method":"Review synthesizing protein complex studies, nuclear translocation assays, signaling pathway inhibitor studies","journal":"Protein & cell","confidence":"Medium","confidence_rationale":"Tier 3 — review article synthesizing primary data from multiple labs on CAR signaling regulation","pmids":["24474196"],"is_preprint":false},{"year":2018,"finding":"Genome-wide characterization of CAR (NR1I3) binding in mouse liver after drug activation shows that CAR-linked genes are either stimulated or inhibited; stimulation but not inhibition correlates with increased H4K5 acetylation. Transcriptional inhibition occurs when CAR binds together with HNF4α, PPARα, or FXR on the same enhancers, where functional competition among co-bound nuclear receptors regulates metabolic gene expression. Drug-activated CAR displaces these endogenous metabolic regulators, constitutively altering metabolic gene regulation.","method":"ChIP-seq for CAR, RXRα, and H4K5Ac genome-wide in mouse liver; gene expression analysis","journal":"iScience","confidence":"High","confidence_rationale":"Tier 1 — genome-wide ChIP-seq with integrated transcriptomics; mechanistically identifies competitive binding with HNF4α, PPARα, FXR at shared enhancers","pmids":["30396153"],"is_preprint":false},{"year":2021,"finding":"In human liver cancer, CAR (NR1I3) plays a tumor-suppressive role distinct from its pro-tumorigenic role in rodent models; CAR drives differentiation and liver regeneration and regulates liver cancer stem cells in human hepatocytes. Species differences in CAR activity mean that the rodent liver tumorigenesis mechanism is not applicable to humans.","method":"Review of human hepatocyte studies, liver cancer models; primary CAR activation/loss-of-function experiments in human liver cancer cells","journal":"Biochimica et biophysica acta. Reviews on cancer","confidence":"Low","confidence_rationale":"Tier 3 — review article; underlying primary mechanistic data not detailed in abstract","pmids":["33529650"],"is_preprint":false}],"current_model":"NR1I3 (CAR) is a liver-enriched orphan nuclear receptor that forms a constitutively active heterodimer with RXRα, maintained in the active conformation by a unique Helix X that stabilizes the AF2 helix; it is held in a cytoplasmic protein complex until activated by direct ligand binding or indirect (ligand-independent) signaling-mediated nuclear translocation, whereupon it transactivates target genes (CYP2B6, CYP3A4, CYP2C8, CYP2C9, UGT1A1, and bilirubin-clearance genes) by binding DR-5/ER-6 response elements as an RXRα heterodimer and recruiting coactivators, while also inhibiting PPARα/HNF4α/FXR-dependent metabolic gene programs through competitive co-occupancy of shared enhancers, with its activity suppressed by endogenous androstane inverse agonists and by IL-1β/NF-κB-mediated chromatin remodeling at the CAR promoter."},"narrative":{"teleology":[{"year":1994,"claim":"The initial cloning of NR1I3 (MB67) established it as a liver-enriched orphan nuclear receptor that heterodimerizes with RXR and exhibits constitutive (ligand-independent) transactivation on DR-5 elements, posing the question of how a nuclear receptor could be active without a known ligand.","evidence":"Receptor cloning, gel shift assays, and reporter assays in transfected cells","pmids":["8114692"],"confidence":"High","gaps":["No endogenous ligand identified","Mechanism of constitutive activity unknown","In vivo target genes undetermined"]},{"year":1998,"claim":"The mystery of constitutive activity was resolved by showing that CAR recruits coactivators without ligand, while androstanol and androstenol function as inverse agonists that release coactivators, defining a novel regulatory paradigm for nuclear receptors.","evidence":"In vitro coactivator interaction assays with stereospecific androstane structure-activity analysis","pmids":["9783588"],"confidence":"High","gaps":["Structural basis for constitutive coactivator docking unknown","Physiological relevance of androstane inverse agonism in vivo unconfirmed"]},{"year":2000,"claim":"Demonstration that CAR and PXR cross-regulate each other's target CYP genes through shared response elements established the concept of an overlapping xenobiotic sensor network rather than a one-receptor-one-target model.","evidence":"Reporter assays and transgenic mouse studies across CYP2B and CYP3A promoters","pmids":["11114890"],"confidence":"High","gaps":["Genome-wide extent of overlap not mapped","Mechanisms determining preferential receptor usage at shared elements unclear"]},{"year":2002,"claim":"Genetic loss-of-function studies using CAR-null mice proved that CAR is required for acetaminophen hepatotoxicity and mapped specific CAR-dependent CYP target genes essential for acetaminophen bioactivation, linking CAR activity directly to drug toxicity outcomes.","evidence":"CAR knockout mice challenged with acetaminophen; pharmacological rescue with androstanol inverse agonist","pmids":["12376703"],"confidence":"High","gaps":["Human relevance of CAR-dependent acetaminophen toxicity not directly tested","Full spectrum of CAR-regulated acetaminophen-metabolizing enzymes not enumerated"]},{"year":2003,"claim":"CAR was shown to coordinate the entire bilirubin-clearance pathway (uptake, conjugation, excretion), with bilirubin itself acting as a direct CAR activator; low neonatal CAR expression was linked to neonatal jaundice susceptibility, establishing CAR's role in endobiotic homeostasis beyond xenobiotic sensing.","evidence":"CAR knockout and humanized CAR mouse models with bilirubin clearance assays and receptor activation studies","pmids":["12644704"],"confidence":"High","gaps":["Direct structural evidence for bilirubin binding to CAR LBD absent","Contribution of CAR variants to clinical neonatal jaundice not tested"]},{"year":2003,"claim":"Identification of CITCO as the first selective human CAR agonist provided a critical pharmacological tool, enabling distinction of CAR- vs PXR-mediated gene regulation and confirming CYP2B6 as a prototypical CAR target gene.","evidence":"Fluorescence-based receptor activation, nuclear translocation assay, and primary human hepatocyte gene expression profiling","pmids":["12611900"],"confidence":"High","gaps":["CITCO selectivity in vivo at physiological doses not fully established","Structural basis for CITCO selectivity over PXR unknown"]},{"year":2004,"claim":"The crystal structure of the CAR/RXRα heterodimer revealed a unique single-turn Helix X that restricts AF-2 conformational freedom, providing the structural explanation for constitutive coactivator recruitment and answering the long-standing question of how CAR achieves ligand-independent activity.","evidence":"X-ray crystallography of the human CAR/RXRα heterodimer complex","pmids":["15610735"],"confidence":"High","gaps":["Structure of CAR bound to inverse agonist not resolved","Dynamics of Helix X upon androstanol binding not captured"]},{"year":2004,"claim":"IL-1β/NF-κB was found to suppress CAR expression via interference with GR-mediated CAR promoter transactivation and chromatin remodeling (reduced H4 acetylation), providing a molecular mechanism for inflammation-mediated downregulation of drug metabolism.","evidence":"ChIP, reporter assays, NF-κB overexpression/inhibitor studies in human hepatocytes","pmids":["15382119"],"confidence":"High","gaps":["Contribution of additional inflammatory cytokines to CAR suppression not systematically studied","In vivo chromatin remodeling at the CAR locus during inflammation not confirmed"]},{"year":2005,"claim":"Chronic CAR activation was shown to cause hepatocarcinogenesis in mice through direct upregulation of Mdm2 and suppression of p53-mediated apoptosis, identifying a specific oncogenic mechanism and distinguishing acute protective xenobiotic responses from chronic tumorigenic risk.","evidence":"CAR knockout mouse carcinogenesis models with Mdm2 expression analysis and apoptosis/DNA replication assays","pmids":["15831521"],"confidence":"High","gaps":["Human relevance disputed — evidence suggests tumor-suppressive role of CAR in human liver","Direct CAR binding to the Mdm2 promoter not confirmed by ChIP"]},{"year":2008,"claim":"CAR was established as a metabolic regulator beyond drug metabolism: its activation suppresses PPARα expression and fatty acid oxidation genes, increasing serum triglycerides, while CAR deletion normalizes hypertriglyceridemia in obese mice.","evidence":"Car knockout crossed with ob/ob mice, high-fat diet model, TCPOBOP activation, PPARα target gene and fatty acid oxidation assays","pmids":["18941143"],"confidence":"High","gaps":["Whether CAR directly binds PPARα regulatory elements or acts indirectly unknown","Human metabolic relevance of CAR-PPARα antagonism not established"]},{"year":2018,"claim":"Genome-wide ChIP-seq in mouse liver revealed that CAR stimulates target genes with increased H4K5 acetylation but inhibits metabolic genes by co-binding enhancers occupied by HNF4α, PPARα, and FXR, establishing competitive enhancer co-occupancy as the mechanism for CAR-mediated metabolic reprogramming.","evidence":"ChIP-seq for CAR, RXRα, and H4K5Ac genome-wide in drug-activated mouse liver integrated with transcriptomics","pmids":["30396153"],"confidence":"High","gaps":["Human liver ChIP-seq for CAR not performed","Coactivator/corepressor dynamics at competitively bound enhancers not resolved","Single-cell heterogeneity of CAR-bound enhancer states not addressed"]},{"year":null,"claim":"Key unresolved questions include the structural basis of inverse agonist-induced conformational change, the identity and regulation of the cytoplasmic CAR retention complex components, species-specific differences in CAR's role in liver tumorigenesis versus tumor suppression, and the genome-wide CAR cistrome in human liver.","evidence":"","pmids":[],"confidence":"Low","gaps":["No inverse agonist-bound CAR crystal structure","Cytoplasmic retention complex composition incompletely defined","Human hepatic CAR ChIP-seq data lacking"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,2,5,7,8,13,22]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,1,5,6,12,22]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[2,17,22]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[7,11,19,21,22]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[21]}],"pathway":[{"term_id":"R-HSA-9748784","term_label":"Drug ADME","supporting_discovery_ids":[3,4,5,6,7,8,9,15]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[8,9,17,18,22]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[16,21,22]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[14,23]}],"complexes":["CAR/RXRα heterodimer"],"partners":["RXRA","NR1I2","HNF4A","PPARA","NR1H4","SRC1","RELA"],"other_free_text":[]},"mechanistic_narrative":"NR1I3 (CAR) is a liver-enriched nuclear receptor that functions as a master xenobiotic sensor and transcriptional regulator of hepatic drug metabolism, bilirubin clearance, and energy homeostasis. It heterodimerizes with RXRα and binds DR-5 and ER-6 response elements on target gene promoters (CYP2B6, CYP3A4, CYP2C8, CYP2C9, UGT1A1) with constitutive transcriptional activity conferred by a unique Helix X that locks the AF-2 activation domain in an active conformation, enabling ligand-independent coactivator recruitment; endogenous androstane metabolites act as inverse agonists by promoting coactivator release [PMID:9783588, PMID:15610735]. CAR resides in a cytoplasmic retention complex and translocates to the nucleus upon direct agonist binding (e.g., CITCO) or indirect signal-mediated activation, where it induces phase I/II detoxification enzymes and bilirubin-clearance genes, while suppressing PPARα-, HNF4α-, and FXR-dependent metabolic programs through competitive co-occupancy of shared enhancers [PMID:12611900, PMID:12644704, PMID:30396153]. Chronic CAR activation in rodent liver promotes hepatocarcinogenesis through Mdm2 upregulation and p53 suppression, whereas inflammatory cytokines (IL-1β) suppress CAR transcription via NF-κB-mediated chromatin remodeling at its promoter [PMID:15831521, PMID:15382119]."},"prefetch_data":{"uniprot":{"accession":"Q14994","full_name":"Nuclear receptor subfamily 1 group I member 3","aliases":["Constitutive activator of retinoid response","Constitutive active response","Constitutive androstane receptor","CAR","Orphan nuclear receptor MB67"],"length_aa":352,"mass_kda":39.9,"function":"Binds and transactivates the retinoic acid response elements that control expression of the retinoic acid receptor beta 2 and alcohol dehydrogenase 3 genes. Transactivates both the phenobarbital responsive element module of the human CYP2B6 gene and the CYP3A4 xenobiotic response element","subcellular_location":"Nucleus; Cytoplasm; Cytoplasm, cytoskeleton","url":"https://www.uniprot.org/uniprotkb/Q14994/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NR1I3","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/NR1I3","total_profiled":1310},"omim":[{"mim_id":"617768","title":"KLEEFSTRA SYNDROME 2; KLEFS2","url":"https://www.omim.org/entry/617768"},{"mim_id":"616936","title":"CHROMODOMAIN HELICASE DNA-BINDING PROTEIN 9; CHD9","url":"https://www.omim.org/entry/616936"},{"mim_id":"610253","title":"KLEEFSTRA SYNDROME 1; KLEFS1","url":"https://www.omim.org/entry/610253"},{"mim_id":"606833","title":"LYSINE-SPECIFIC METHYLTRANSFERASE 2C; KMT2C","url":"https://www.omim.org/entry/606833"},{"mim_id":"604630","title":"NUCLEAR RECEPTOR SUBFAMILY 0, GROUP B, MEMBER 2; NR0B2","url":"https://www.omim.org/entry/604630"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"liver","ntpm":158.8}],"url":"https://www.proteinatlas.org/search/NR1I3"},"hgnc":{"alias_symbol":["MB67","CAR1","CAR"],"prev_symbol":[]},"alphafold":{"accession":"Q14994","domains":[{"cath_id":"3.30.50.10","chopping":"21-101","consensus_level":"high","plddt":93.2059,"start":21,"end":101},{"cath_id":"1.10.565.10","chopping":"109-352","consensus_level":"high","plddt":91.3401,"start":109,"end":352}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14994","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q14994-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q14994-F1-predicted_aligned_error_v6.png","plddt_mean":90.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NR1I3","jax_strain_url":"https://www.jax.org/strain/search?query=NR1I3"},"sequence":{"accession":"Q14994","fasta_url":"https://rest.uniprot.org/uniprotkb/Q14994.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q14994/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14994"}},"corpus_meta":[{"pmid":"35361234","id":"PMC_35361234","title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.","date":"2022","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/35361234","citation_count":520,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30680780","id":"PMC_30680780","title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer.","date":"2019","source":"American journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/30680780","citation_count":411,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30875739","id":"PMC_30875739","title":"Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30875739","citation_count":408,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28652918","id":"PMC_28652918","title":"Engineering CAR-T cells.","date":"2017","source":"Biomarker research","url":"https://pubmed.ncbi.nlm.nih.gov/28652918","citation_count":408,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12120277","id":"PMC_12120277","title":"PXR, CAR and drug metabolism.","date":"2002","source":"Nature reviews. Drug discovery","url":"https://pubmed.ncbi.nlm.nih.gov/12120277","citation_count":400,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34861191","id":"PMC_34861191","title":"An NK-like CAR T cell transition in CAR T cell dysfunction.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/34861191","citation_count":314,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39134804","id":"PMC_39134804","title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors.","date":"2024","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39134804","citation_count":229,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36097223","id":"PMC_36097223","title":"Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy.","date":"2022","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36097223","citation_count":204,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19595610","id":"PMC_19595610","title":"PXR and CAR in energy metabolism.","date":"2009","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/19595610","citation_count":199,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22554043","id":"PMC_22554043","title":"Role of CAR and PXR in xenobiotic sensing and metabolism.","date":"2012","source":"Expert opinion on drug metabolism & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/22554043","citation_count":190,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32714329","id":"PMC_32714329","title":"Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32714329","citation_count":187,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36765623","id":"PMC_36765623","title":"CAR-T: What Is Next?","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36765623","citation_count":173,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31221182","id":"PMC_31221182","title":"Target selection for CAR-T therapy.","date":"2019","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31221182","citation_count":157,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27231717","id":"PMC_27231717","title":"CAR models: next-generation CAR modifications for enhanced T-cell function.","date":"2016","source":"Molecular therapy oncolytics","url":"https://pubmed.ncbi.nlm.nih.gov/27231717","citation_count":137,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38012406","id":"PMC_38012406","title":"Forks in the road for CAR T and CAR NK cell cancer therapies.","date":"2023","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38012406","citation_count":134,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1849108","id":"PMC_1849108","title":"Gene targeting of the aggregation stage cAMP receptor cAR1 in Dictyostelium.","date":"1991","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/1849108","citation_count":134,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33168929","id":"PMC_33168929","title":"Counteracting CAR T cell dysfunction.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33168929","citation_count":129,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34429382","id":"PMC_34429382","title":"Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function.","date":"2021","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/34429382","citation_count":125,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30369931","id":"PMC_30369931","title":"Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30369931","citation_count":123,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22889594","id":"PMC_22889594","title":"Targeting xenobiotic receptors PXR and CAR for metabolic diseases.","date":"2012","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/22889594","citation_count":121,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35278370","id":"PMC_35278370","title":"3D-organoid culture supports differentiation of human CAR+ iPSCs into highly functional CAR T cells.","date":"2022","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/35278370","citation_count":116,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22308384","id":"PMC_22308384","title":"Ancestral capture of syncytin-Car1, a fusogenic endogenous retroviral envelope gene involved in placentation and conserved in Carnivora.","date":"2012","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22308384","citation_count":105,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35203496","id":"PMC_35203496","title":"CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications.","date":"2022","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/35203496","citation_count":100,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12573482","id":"PMC_12573482","title":"Functional and structural comparison of PXR and CAR.","date":"2003","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/12573482","citation_count":100,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34422667","id":"PMC_34422667","title":"From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34422667","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24667955","id":"PMC_24667955","title":"CD19-CAR trials.","date":"2014","source":"Cancer journal (Sudbury, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/24667955","citation_count":94,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18941143","id":"PMC_18941143","title":"The nuclear receptor CAR (NR1I3) regulates serum triglyceride levels under conditions of metabolic stress.","date":"2008","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/18941143","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24474196","id":"PMC_24474196","title":"Signaling control of the constitutive androstane receptor (CAR).","date":"2014","source":"Protein & cell","url":"https://pubmed.ncbi.nlm.nih.gov/24474196","citation_count":88,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36429120","id":"PMC_36429120","title":"CAR-Macrophages and CAR-T Cells Synergistically Kill Tumor Cells In Vitro.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36429120","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29370379","id":"PMC_29370379","title":"Glycan-directed CAR-T cells.","date":"2018","source":"Glycobiology","url":"https://pubmed.ncbi.nlm.nih.gov/29370379","citation_count":78,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28718815","id":"PMC_28718815","title":"Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy.","date":"2017","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/28718815","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36179026","id":"PMC_36179026","title":"CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/36179026","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27592405","id":"PMC_27592405","title":"Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.","date":"2016","source":"Cytotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/27592405","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38865661","id":"PMC_38865661","title":"Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy.","date":"2024","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38865661","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16099843","id":"PMC_16099843","title":"Retinoid X receptor-alpha-dependent transactivation by a naturally occurring structural variant of human constitutive androstane receptor (NR1I3).","date":"2005","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16099843","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33463538","id":"PMC_33463538","title":"Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes.","date":"2021","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/33463538","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29107016","id":"PMC_29107016","title":"Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies.","date":"2017","source":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29107016","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26921498","id":"PMC_26921498","title":"Small-molecule modulators of PXR and CAR.","date":"2016","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/26921498","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31114756","id":"PMC_31114756","title":"A Metabolism Toolbox for CAR T Therapy.","date":"2019","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31114756","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38143263","id":"PMC_38143263","title":"Trogocytosis of CAR molecule regulates CAR-T cell dysfunction and tumor antigen escape.","date":"2023","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/38143263","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37932456","id":"PMC_37932456","title":"Harnessing CD3 diversity to optimize CAR T cells.","date":"2023","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37932456","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37124148","id":"PMC_37124148","title":"Non-viral chimeric antigen receptor (CAR) T cells going viral.","date":"2023","source":"Immuno-oncology technology","url":"https://pubmed.ncbi.nlm.nih.gov/37124148","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35149294","id":"PMC_35149294","title":"Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages.","date":"2022","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35149294","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26791002","id":"PMC_26791002","title":"Chimeric Antigen Receptor (CAR) therapy for multiple myeloma.","date":"2016","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/26791002","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37205115","id":"PMC_37205115","title":"Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37205115","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16109509","id":"PMC_16109509","title":"What does it take to bind CAR?","date":"2005","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/16109509","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40379910","id":"PMC_40379910","title":"In vivo CAR engineering for immunotherapy.","date":"2025","source":"Nature reviews. Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/40379910","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30549299","id":"PMC_30549299","title":"Treating osteosarcoma with CAR T cells.","date":"2019","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30549299","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38039964","id":"PMC_38039964","title":"ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells.","date":"2023","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/38039964","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38067179","id":"PMC_38067179","title":"AhR, PXR and CAR: From Xenobiotic Receptors to Metabolic Sensors.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/38067179","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32139020","id":"PMC_32139020","title":"CAR T and CAR NK cells in multiple myeloma: Expanding the targets.","date":"2020","source":"Best practice & research. Clinical haematology","url":"https://pubmed.ncbi.nlm.nih.gov/32139020","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12747555","id":"PMC_12747555","title":"Adenovirus interaction with its cellular receptor CAR.","date":"2003","source":"Current topics in microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12747555","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19686701","id":"PMC_19686701","title":"Retinoids activate RXR/CAR-mediated pathway and induce CYP3A.","date":"2009","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19686701","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28545889","id":"PMC_28545889","title":"CAR: A key regulator of adhesion and inflammation.","date":"2017","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/28545889","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35392217","id":"PMC_35392217","title":"Special Chimeric Antigen Receptor (CAR) Modifications of T Cells: A Review.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35392217","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7721769","id":"PMC_7721769","title":"Agonist-induced loss of ligand binding is correlated with phosphorylation of cAR1, a G protein-coupled chemoattractant receptor from Dictyostelium.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7721769","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34943898","id":"PMC_34943898","title":"NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34943898","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36831396","id":"PMC_36831396","title":"CAR-T-Derived Extracellular Vesicles: A Promising Development of CAR-T Anti-Tumor Therapy.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36831396","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32163104","id":"PMC_32163104","title":"Challenges of CAR- and TCR-T cell-based therapy for chronic infections.","date":"2020","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32163104","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23729557","id":"PMC_23729557","title":"An update on the constitutive androstane receptor (CAR).","date":"2013","source":"Drug metabolism and drug interactions","url":"https://pubmed.ncbi.nlm.nih.gov/23729557","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37403182","id":"PMC_37403182","title":"Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies.","date":"2023","source":"Biomarker research","url":"https://pubmed.ncbi.nlm.nih.gov/37403182","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29568411","id":"PMC_29568411","title":"The development of CAR design for tumor CAR-T cell therapy.","date":"2018","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29568411","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31723811","id":"PMC_31723811","title":"CAR T Cells: A Snapshot on the Growing Options to Design a CAR.","date":"2019","source":"HemaSphere","url":"https://pubmed.ncbi.nlm.nih.gov/31723811","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22098234","id":"PMC_22098234","title":"Constitutive androstane receptor (CAR) is a xenosensor and target for therapy.","date":"2011","source":"Biochemistry. Biokhimiia","url":"https://pubmed.ncbi.nlm.nih.gov/22098234","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40179881","id":"PMC_40179881","title":"Engineering sonogenetic EchoBack-CAR T cells.","date":"2025","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/40179881","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32402724","id":"PMC_32402724","title":"Revving the CAR - Combination strategies to enhance CAR T cell effectiveness.","date":"2020","source":"Blood reviews","url":"https://pubmed.ncbi.nlm.nih.gov/32402724","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8830781","id":"PMC_8830781","title":"The cell density factor CMF regulates the chemoattractant receptor cAR1 in Dictyostelium.","date":"1996","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/8830781","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39079964","id":"PMC_39079964","title":"A CAR enhancer increases the activity and persistence of CAR T cells.","date":"2024","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/39079964","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32301017","id":"PMC_32301017","title":"CAR T-Cells.","date":"2020","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/32301017","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37877819","id":"PMC_37877819","title":"CAR-macrophage versus CAR-T for solid tumors: The race between a rising star and a superstar.","date":"2024","source":"Biomolecules & biomedicine","url":"https://pubmed.ncbi.nlm.nih.gov/37877819","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39889712","id":"PMC_39889712","title":"CAR T cells, CAR NK cells, and CAR macrophages exhibit distinct traits in glioma models but are similarly enhanced when combined with cytokines.","date":"2025","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39889712","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39101835","id":"PMC_39101835","title":"Redirecting B7-H3.CAR T Cells to Chemokines Expressed in Osteosarcoma Enhances Homing and Antitumor Activity in Preclinical Models.","date":"2024","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/39101835","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31181279","id":"PMC_31181279","title":"The making and function of CAR cells.","date":"2019","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/31181279","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33249047","id":"PMC_33249047","title":"CAR T-cells profiling in carcinogenesis and tumorigenesis: An overview of CAR T-cells cancer therapy.","date":"2020","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33249047","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24351870","id":"PMC_24351870","title":"Association of hemoglobin levels, CYP3A5, and NR1I3 gene polymorphisms with tacrolimus pharmacokinetics in liver transplant patients.","date":"2013","source":"Drug metabolism and pharmacokinetics","url":"https://pubmed.ncbi.nlm.nih.gov/24351870","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29772559","id":"PMC_29772559","title":"GITR domain inside CAR co-stimulates activity of CAR-T cells against cancer.","date":"2018","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/29772559","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16101576","id":"PMC_16101576","title":"Beyond CAR and PXR.","date":"2005","source":"Current drug metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16101576","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38090576","id":"PMC_38090576","title":"Advancing CAR-based immunotherapies in solid tumors: CAR- macrophages and neutrophils.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38090576","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31611880","id":"PMC_31611880","title":"CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31611880","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36700225","id":"PMC_36700225","title":"CAR T cell therapy becomes CHIC: \"cytokine help intensified CAR\" T cells.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36700225","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35259043","id":"PMC_35259043","title":"Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia.","date":"2022","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/35259043","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30396153","id":"PMC_30396153","title":"Binding of Drug-Activated CAR/Nr1i3 Alters Metabolic Regulation in the Liver.","date":"2018","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/30396153","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38745250","id":"PMC_38745250","title":"CAR T cells outperform CAR NK cells in CAR-mediated effector functions in head-to-head comparison.","date":"2024","source":"Experimental hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/38745250","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35005887","id":"PMC_35005887","title":"Synthetic Biology in Chimeric Antigen Receptor T (CAR T) Cell Engineering.","date":"2022","source":"ACS synthetic biology","url":"https://pubmed.ncbi.nlm.nih.gov/35005887","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33529650","id":"PMC_33529650","title":"Role of the constitutive androstane receptor (CAR) in human liver cancer.","date":"2021","source":"Biochimica et biophysica acta. Reviews on cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33529650","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37715447","id":"PMC_37715447","title":"The physical landscape of CAR-T synapse.","date":"2023","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/37715447","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34582835","id":"PMC_34582835","title":"Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma.","date":"2021","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/34582835","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37080711","id":"PMC_37080711","title":"Infectious complications of chimeric antigen receptor (CAR) T-cell therapies.","date":"2023","source":"Seminars in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/37080711","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28101686","id":"PMC_28101686","title":"Minicircle-Based Engineering of Chimeric Antigen Receptor (CAR) T Cells.","date":"2016","source":"Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28101686","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33575314","id":"PMC_33575314","title":"Novel progresses of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma.","date":"2021","source":"Stem cell investigation","url":"https://pubmed.ncbi.nlm.nih.gov/33575314","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33807867","id":"PMC_33807867","title":"Engineering Metabolism of Chimeric Antigen Receptor (CAR) Cells for Developing Efficient Immunotherapies.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33807867","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36409926","id":"PMC_36409926","title":"Rational Protein Design Yields a CD20 CAR with Superior Antitumor Efficacy Compared with CD19 CAR.","date":"2023","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/36409926","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31492448","id":"PMC_31492448","title":"The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma.","date":"2019","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31492448","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34771581","id":"PMC_34771581","title":"The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34771581","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38766710","id":"PMC_38766710","title":"Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies.","date":"2024","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38766710","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36498890","id":"PMC_36498890","title":"Joining Forces for Cancer Treatment: From \"TCR versus CAR\" to \"TCR and CAR\".","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36498890","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38962014","id":"PMC_38962014","title":"Universal CAR 2.0 to overcome current limitations in CAR therapy.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38962014","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39711794","id":"PMC_39711794","title":"Armoring chimeric antigen receptor (CAR) T cells as micropharmacies for cancer therapy.","date":"2024","source":"Immuno-oncology technology","url":"https://pubmed.ncbi.nlm.nih.gov/39711794","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37968136","id":"PMC_37968136","title":"Building safety into CAR-T therapy.","date":"2023","source":"Human vaccines & immunotherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/37968136","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34554405","id":"PMC_34554405","title":"Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology.","date":"2021","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/34554405","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24816252","id":"PMC_24816252","title":"An atlas of genetic influences on human blood metabolites.","date":"2014","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24816252","citation_count":1209,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19274049","id":"PMC_19274049","title":"A census of human transcription factors: function, expression and evolution.","date":"2009","source":"Nature reviews. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19274049","citation_count":1191,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28473536","id":"PMC_28473536","title":"Impact of cytosine methylation on DNA binding specificities of human transcription factors.","date":"2017","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/28473536","citation_count":934,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939624","id":"PMC_22939624","title":"Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939624","citation_count":708,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8650544","id":"PMC_8650544","title":"An orphan nuclear hormone receptor that lacks a DNA binding domain and heterodimerizes with other receptors.","date":"1996","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8650544","citation_count":441,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9783588","id":"PMC_9783588","title":"Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta.","date":"1998","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9783588","citation_count":405,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11114890","id":"PMC_11114890","title":"Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR and CAR.","date":"2000","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/11114890","citation_count":391,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8114692","id":"PMC_8114692","title":"A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements.","date":"1994","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8114692","citation_count":389,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12611900","id":"PMC_12611900","title":"Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12611900","citation_count":348,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12644704","id":"PMC_12644704","title":"Induction of bilirubin clearance by the constitutive androstane receptor (CAR).","date":"2003","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12644704","citation_count":288,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12644700","id":"PMC_12644700","title":"Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor.","date":"2003","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12644700","citation_count":272,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12376703","id":"PMC_12376703","title":"Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR.","date":"2002","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/12376703","citation_count":250,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15831521","id":"PMC_15831521","title":"Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor.","date":"2005","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/15831521","citation_count":245,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17207965","id":"PMC_17207965","title":"hORFeome v3.1: a resource of human open reading frames representing over 10,000 human genes.","date":"2007","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/17207965","citation_count":222,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9295294","id":"PMC_9295294","title":"Differential transactivation by two isoforms of the orphan nuclear hormone receptor CAR.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9295294","citation_count":218,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21988832","id":"PMC_21988832","title":"Toward an understanding of the protein interaction network of the human liver.","date":"2011","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/21988832","citation_count":207,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12130689","id":"PMC_12130689","title":"Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor.","date":"2002","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12130689","citation_count":188,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15610735","id":"PMC_15610735","title":"A structural basis for constitutive activity in the human CAR/RXRalpha heterodimer.","date":"2004","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/15610735","citation_count":178,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15252010","id":"PMC_15252010","title":"The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR).","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15252010","citation_count":162,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15933212","id":"PMC_15933212","title":"Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha.","date":"2005","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15933212","citation_count":153,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15382119","id":"PMC_15382119","title":"Interleukin 1beta inhibits CAR-induced expression of hepatic genes involved in drug and bilirubin clearance.","date":"2004","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/15382119","citation_count":128,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12181452","id":"PMC_12181452","title":"Regulation of human CYP2C9 by the constitutive androstane receptor: discovery of a new distal binding site.","date":"2002","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12181452","citation_count":127,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19034627","id":"PMC_19034627","title":"Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways.","date":"2008","source":"Pharmaceutical research","url":"https://pubmed.ncbi.nlm.nih.gov/19034627","citation_count":121,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18305370","id":"PMC_18305370","title":"The roles of nuclear receptors CAR and PXR in hepatic energy metabolism.","date":"2008","source":"Drug metabolism and pharmacokinetics","url":"https://pubmed.ncbi.nlm.nih.gov/18305370","citation_count":116,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":38207,"output_tokens":2654,"usd":0.077216},"stage2":{"model":"claude-opus-4-6","input_tokens":5931,"output_tokens":2367,"usd":0.133245},"total_usd":0.524235,"stage1_batch_id":"msgbatch_012ZiiCUBfB62NCTQd4Bk1Jo","stage2_batch_id":"msgbatch_01Xuqq9aUHoQouS7UVGZNStZ","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":50503,"output_tokens":6479,"usd":0.124347},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":10007,"output_tokens":3050,"usd":0.189427}},"stage1_raw":"Looking at the corpus, I need to identify papers about NR1I3 (the constitutive androstane receptor, CAR). Most papers in this corpus are about CAR T-cell immunotherapy (a completely different \"CAR\"), which is a symbol collision. I need to focus only on papers describing NR1I3/CAR as a nuclear receptor.\n\nRelevant papers: #5, #9, #10, #20, #24, #27, #28, #35, #38, #50, #53, #60, #64, #75, #82, #85\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"NR1I3 (CAR) was identified as a transcriptional regulator of cytochrome P450 expression that couples xenobiotic exposure to oxidative metabolism, functioning as a xenobiotic sensor alongside PXR.\",\n      \"method\": \"Gene expression assays, reporter assays, in vivo xenobiotic exposure studies\",\n      \"journal\": \"Nature reviews. Drug discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple independent labs, replicated across multiple experimental systems\",\n      \"pmids\": [\"12120277\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"NR1I3 (CAR) and PXR were compared by gene expression assays, cell-based ligand profiling, and crystallographic/structural modeling, revealing key functional and structural differences between the two xenosensors.\",\n      \"method\": \"Gene expression assays, cell-based ligand profiling, crystallography/structural modeling\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystallographic structure combined with functional assays\",\n      \"pmids\": [\"12573482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"The human CAR splice variant CAR3 (containing a 5 amino acid insertion in the ligand binding domain) is ligand-activated (not constitutively active), transactivating DR-4 and natural CYP2B6/CYP3A4 enhancers in response to CITCO; this response requires the DNA binding domain and AF-2 motif and is markedly enhanced by RXRα cotransfection through an RXR AF-2-dependent mechanism that facilitates coactivator (SRC-1) recruitment.\",\n      \"method\": \"Transient transfection reporter assays, mammalian two-hybrid assay, site-directed mutagenesis\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (reporter assay, mutagenesis, mammalian two-hybrid) in single rigorous study\",\n      \"pmids\": [\"16099843\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"NR1I3 (CAR) regulates serum triglyceride levels under metabolic stress: Car-/- mice on ob/ob background or high-fat diet showed normalized triglycerides; CAR activation with TCPOBOP increased triglycerides in a CAR-dependent manner and suppressed PPARα target gene expression (Cyp4a14, CPT1α, CTE), reducing hepatic fatty acid oxidation.\",\n      \"method\": \"Genetic knockout (Car-/- mice), pharmacological activation (TCPOBOP), gene expression analysis\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined metabolic phenotype, pharmacological rescue, replicated across multiple dietary models\",\n      \"pmids\": [\"18941143\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Retinoids activate RXR/CAR-mediated pathway and induce CYP3A expression; retinoids activate RXRα/CAR and RXRγ/CAR heterodimers, and chromatin immunoprecipitation showed that retinoids recruit RXRα and CAR to the proximal ER6 and distal XREM nuclear receptor response elements of the CYP3A4 gene promoter.\",\n      \"method\": \"Transient transfection luciferase reporter assay, chromatin immunoprecipitation (ChIP)\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus reporter assay, single lab\",\n      \"pmids\": [\"19686701\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"NR1I3 (CAR) and PXR regulate energy metabolism including fatty acid, lipid, and glucose metabolism through direct gene regulation and crosstalk with other transcriptional regulators such as PPARα.\",\n      \"method\": \"Review synthesizing genetic and pharmacological studies in animal models\",\n      \"journal\": \"Trends in endocrinology and metabolism: TEM\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — review synthesizing multiple experimental findings from independent labs\",\n      \"pmids\": [\"19595610\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"NR1I3 (CAR) forms a protein complex in the cytoplasm in the absence of activation, and can be activated by either direct ligand binding or ligand-independent (indirect) mechanisms, both resulting in nuclear translocation from the cytoplasm; indirect activation is exclusively involved in nuclear translocation through signaling pathways.\",\n      \"method\": \"Review summarizing protein complex studies, nuclear translocation assays, signaling pathway analyses\",\n      \"journal\": \"Drug metabolism and drug interactions\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — review compiling multiple experimental findings, indirect activation mechanism partially characterized\",\n      \"pmids\": [\"23729557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"NR1I3 polymorphisms in donor liver are associated with tacrolimus pharmacokinetics (dose-adjusted trough concentrations) in liver transplant patients, consistent with CAR's role in regulating CYP3A expression.\",\n      \"method\": \"Pharmacogenetic association study with genotyping and multiple linear regression\",\n      \"journal\": \"Drug metabolism and pharmacokinetics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 — association study, no direct mechanistic experiment on NR1I3 function\",\n      \"pmids\": [\"24351870\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CAR (NR1I3) can be activated by ligand-independent (indirect) mechanisms involving nuclear translocation from a cytoplasmic protein complex; accumulating evidence indicates multiple signaling pathways affect CAR nuclear accumulation.\",\n      \"method\": \"Review of protein complex studies, phosphorylation experiments, nuclear translocation assays\",\n      \"journal\": \"Protein & cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 + Strong — review synthesizing multiple mechanistic studies from independent labs\",\n      \"pmids\": [\"24474196\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Drug-activated CAR (Nr1i3) binds genome-wide with its partner RXRα and induces H4K5 acetylation on CAR-linked genes regulating lipid, carbohydrate, and energy metabolism as well as detoxification; transcriptional inhibition occurs when CAR binds with HNF4α, PPARα, or FXR on the same enhancers through functional competition among nuclear receptors.\",\n      \"method\": \"ChIP-seq (genome-wide CAR and RXRα binding), histone acetylation profiling (H4K5Ac), gene expression analysis in mouse liver\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genome-wide ChIP-seq with functional gene expression validation, mechanistically rigorous\",\n      \"pmids\": [\"30396153\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CAR (NR1I3) has a tumour-suppressive role in human liver cancer and drives hepatocyte differentiation and liver regeneration; it regulates liver cancer stem cells and interacts with key signalling pathways involved in drug, energy, and bilirubin metabolism, with important species differences between rodent and human CAR activity.\",\n      \"method\": \"Review of human liver CAR studies, loss-of-function and gain-of-function cellular assays, cancer stem cell analyses\",\n      \"journal\": \"Biochimica et biophysica acta. Reviews on cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 + Moderate — review compiling multiple experimental findings including functional cellular assays\",\n      \"pmids\": [\"33529650\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"NR1I3 (CAR) functions as a metabolic sensor regulating lipid metabolism and dyslipidemia, in addition to its established role as a xenobiotic receptor, through transcriptional regulation of key metabolic enzymes.\",\n      \"method\": \"Review synthesizing receptor activation studies, lipid metabolism assays, and gene regulation experiments\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 + Weak — review with limited primary mechanistic data cited\",\n      \"pmids\": [\"38067179\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NR1I3 (CAR) is a liver-enriched nuclear receptor that resides in a cytoplasmic protein complex in its inactive state and translocates to the nucleus upon activation by either direct ligand binding or ligand-independent signaling mechanisms; once nuclear, it heterodimerizes with RXRα and binds response elements (including DR-4, ER6, and XREM sites) in promoters of CYP2B6, CYP3A4, and other drug-metabolizing enzymes to drive xenobiotic detoxification, while also competing with HNF4α, PPARα, and FXR on shared enhancers to alter lipid, glucose, and energy metabolism, and exhibiting a tumor-suppressive role in human hepatocytes.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper first, then extract discoveries only from KEPT papers.\n\n**Classification:**\n\nThe query gene NR1I3 encodes the **Constitutive Androstane Receptor (CAR)**, a nuclear hormone receptor involved in xenobiotic metabolism, drug metabolism, and energy homeostasis.\n\n**EXCLUDE** (alias collision - CAR = Chimeric Antigen Receptor, unrelated to NR1I3):\nPapers [1]-[4], [6]-[8], [11]-[15], [17]-[19], [21], [23], [25]-[26], [29]-[34], [36]-[37], [39]-[43], [45], [47]-[49], [51], [55], [57]-[59], [61]-[63], [65]-[66], [68]-[71], [73]-[74], [76], [78]-[81], [83]-[84], [86]-[100]\n\n**EXCLUDE** (alias collision - CAR = coxsackievirus and adenovirus receptor):\nPapers [46], [52], [54]\n\n**EXCLUDE** (alias collision - cAR1 = Dictyostelium cAMP receptor):\nPapers [16], [56], [67]\n\n**EXCLUDE** (alias collision - syncytin-Car1, carnivora):\nPaper [22]\n\n**KEEP** (papers about NR1I3/CAR nuclear receptor):\n[5], [9], [10], [20], [24], [27], [28], [35], [38], [50], [53], [60], [64], [75], [77], [82], [85]\n\nFrom gene2pubmed curated papers — all about NR1I3:\n[10], [12]-[19], [21], [23]-[30], [27], [28], [29], [30]\n\nNow extracting discoveries from KEPT papers:\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"NR1I3 (MB67) was identified as an orphan nuclear hormone receptor predominantly expressed in liver that binds and transactivates retinoic acid response elements (DR5 motifs) as a heterodimer with RXR, exhibiting constitutive (ligand-independent) transactivation activity dependent on the AF-2 motif.\",\n      \"method\": \"Receptor cloning, gel shift assays, transient transfection/reporter assays, RXR heterodimerization studies\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — original cloning with multiple orthogonal functional assays; foundational paper replicated by subsequent work\",\n      \"pmids\": [\"8114692\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"NR1I3 (hCAR/mCAR) acts as a constitutive transcriptional activator that heterodimerizes with RXR to bind retinoic acid response elements; a truncated splice variant mCAR2 lacking part of the ligand-binding/dimerization domain fails to bind DNA or transactivate, and also cannot inhibit mCAR1/hCAR activity.\",\n      \"method\": \"Gene cloning, transient transfection reporter assays, gel shift/DNA binding assays, dominant-negative analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods in original discovery paper, replicated across labs\",\n      \"pmids\": [\"9295294\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CAR-beta (NR1I3) constitutive transcriptional activity results from ligand-independent recruitment of transcriptional co-activators; androstanol and androstenol (3α-hydroxy, 5α-reduced androstanes) function as inverse agonists by promoting co-activator release from the ligand-binding domain without affecting heterodimerization or DNA binding, defining a class of naturally occurring nuclear receptor inverse agonists.\",\n      \"method\": \"In vitro transcription/reporter assays, ligand-binding studies, co-activator interaction assays, steroid structure-activity analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution of co-activator recruitment/release mechanism with stereospecificity analysis; published in Nature and widely replicated\",\n      \"pmids\": [\"9783588\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CAR (NR1I3) can activate CYP3A genes through PXR/SXR response elements, and conversely PXR/SXR can activate CYP2B genes through the phenobarbital response element (PBRE), demonstrating cross-regulatory overlap between these two xenobiotic receptors in regulating multiple CYP gene classes.\",\n      \"method\": \"Cell-based reporter assays, transgenic mouse studies, gene expression analysis\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic (transgenic) and biochemical evidence from multiple CYP gene promoters; replicated in vivo\",\n      \"pmids\": [\"11114890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CAR (NR1I3) regulates acetaminophen metabolism and hepatotoxicity by inducing expression of three acetaminophen-metabolizing enzymes (including CYP enzymes); CAR null mice are resistant to acetaminophen toxicity, and administration of the inverse agonist androstanol 1 hour after acetaminophen treatment blocked hepatotoxicity in wild-type but not CAR null mice.\",\n      \"method\": \"CAR knockout mouse studies, gene expression analysis, in vivo hepatotoxicity model, pharmacological inverse agonist administration\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout with pharmacological rescue, published in Science; defines CAR as a key regulator of acetaminophen metabolism\",\n      \"pmids\": [\"12376703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CAR (NR1I3) transcriptionally activates CYP3A4 through two high-affinity binding motifs located ~7720 and ~150 bp upstream of the transcription start site, requiring cooperativity between the proximal promoter and the distal xenobiotic-responsive enhancer module (XREM); these CAR response elements also mediate transactivation by PXR.\",\n      \"method\": \"Transient transfection reporter assays, gel shift assays, in vitro and in vivo CAR activation, primary human hepatocyte studies\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — promoter mapping with gel shifts and reporter assays plus in vivo validation; widely replicated\",\n      \"pmids\": [\"12130689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CAR (NR1I3) constitutively regulates CYP2C9 expression through a newly identified distal CAR-responsive enhancer (CAR-RE) located between -2900 and -2841 bp of the CYP2C9 promoter, containing two DR-5 nuclear receptor binding motifs that bind hCAR, mCAR, and human PXR.\",\n      \"method\": \"Transfection assays, gel shift assays, mRNA quantification in HepG2 cells\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gel shift and reporter assays identify specific binding motifs; single lab study\",\n      \"pmids\": [\"12181452\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CITCO was identified as the first selective human CAR agonist; it potently activates CAR (NR1I3) in a fluorescence-based assay, is selective over PXR and other nuclear receptors, induces CAR nuclear translocation, and induces the prototypical CAR target gene CYP2B6 in primary human hepatocytes. Using CITCO, CAR and PXR activators were shown to differentially regulate overlapping but distinct sets of drug-metabolizing enzyme genes.\",\n      \"method\": \"Fluorescence-based receptor activation assay, nuclear translocation assay, primary human hepatocyte gene expression profiling, selectivity panel against other nuclear receptors\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal assays identifying first selective human CAR agonist; foundational tool paper with broad use\",\n      \"pmids\": [\"12611900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CAR (NR1I3) activates all five components of the bilirubin-clearance pathway in liver; this induction is absent in CAR null mice, is present in mice expressing human CAR, and CAR null mice are defective in clearing chronically elevated bilirubin. Bilirubin itself can directly activate CAR. CAR expression is very low in neonatal liver, suggesting its functional deficit contributes to neonatal jaundice.\",\n      \"method\": \"CAR knockout and humanized mouse models, gene expression analysis, bilirubin clearance assays, receptor activation assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout and humanized mouse models with functional bilirubin clearance readout; replicated findings\",\n      \"pmids\": [\"12644704\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PXR and CAR (NR1I3) both induce specific UGT1A isoforms involved in estrogen, thyroxin, bilirubin, and carcinogen metabolism; transgenic mice expressing constitutively active human PXR show markedly increased UGT activity and steroid clearance, demonstrating that both receptors transduce phase I and phase II adaptive hepatic responses.\",\n      \"method\": \"Transgenic mouse studies, UGT activity assays, gene expression analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo transgenic model with enzymatic activity measurements; defines phase I and II regulatory role\",\n      \"pmids\": [\"12644700\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Functional and structural comparison of PXR (NR1I2) and CAR (NR1I3) reveals key differences in gene expression targets, ligand profiles in cell-based assays, and crystallographic/structural features, highlighting their distinct but overlapping physiological roles as xenosensors.\",\n      \"method\": \"Gene expression assays, cell-based ligand profiling, crystallographic and structural modeling analyses\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — structural and functional comparison with crystallography; single comparative study\",\n      \"pmids\": [\"12573482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The X-ray crystal structure of the human CAR (NR1I3)/RXRα heterodimer reveals that CAR contains a unique single-turn Helix X that restricts conformational freedom of the C-terminal AF2 helix, favoring the active (transcriptionally competent) state without ligand. Helix X and AF2 sit atop four amino acids shielding the CAR ligand-binding pocket. A fatty acid ligand was found in the RXRα binding pocket, and stabilizing interactions from the heterodimer interface hold RXRα in an active conformation, explaining ligand-independent constitutive activation.\",\n      \"method\": \"X-ray crystallography of CAR/RXRα heterodimer, structural analysis of ligand-binding pocket\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure providing direct mechanistic basis for constitutive activity; foundational structural paper\",\n      \"pmids\": [\"15610735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CAR (NR1I3) and PXR both bind to an ER6 motif in the CYP3A5 promoter and transactivate CYP3A5 expression; rifampin induces CYP3A5 mRNA in human hepatocytes and intestinal biopsies via this mechanism, and hepatic PXR expression correlates with CYP3A5 mRNA levels.\",\n      \"method\": \"Reporter assays, gel shift/EMSA, RT-PCR in primary hepatocytes and intestinal biopsies, correlation analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods including primary human tissue; single study\",\n      \"pmids\": [\"15252010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"The human CAR splice variant CAR3 (NR1I3), which has a 5-amino acid insertion in the ligand-binding domain, is ligand-activated (not constitutively active); CITCO and clotrimazole act as activating ligands for CAR3 (clotrimazole is an inverse agonist for the reference CAR1). Transactivation by CAR3 requires its DNA-binding domain and AF-2 motif, is markedly enhanced by RXRα cotransfection through an RXR AF-2-dependent mechanism, and RXR augments CAR3 activity by facilitating coactivator (SRC-1) recruitment.\",\n      \"method\": \"Transient transfection reporter assays, mammalian two-hybrid assays, mutational analysis of AF-2 and DNA-binding domains, RXR cotransfection studies\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including two-hybrid coactivator recruitment assay and domain mutagenesis\",\n      \"pmids\": [\"16099843\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Chronic activation of CAR (NR1I3) causes hepatocarcinogenesis; CAR null mice are completely resistant to tumorigenic effects of chronic xenobiotic stress. In the acute xenobiotic response, CAR directly up-regulates Mdm2 expression, contributing to increased DNA replication and inhibition of p53-mediated apoptosis, linking chronic environmental stress to tumor formation via this specific molecular mechanism.\",\n      \"method\": \"CAR knockout mouse carcinogenesis model, acute xenobiotic stress experiments, Mdm2 expression analysis, apoptosis and DNA replication assays\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout with identified molecular mechanism (Mdm2/p53 pathway); replicated findings\",\n      \"pmids\": [\"15831521\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CAR (NR1I3) and PXR regulate CYP2C8 expression through a distal PXR/CAR-binding site in the CYP2C8 promoter; CITCO (CAR agonist) and rifampicin (PXR agonist) induce CYP2C8 through this site. Additional regulatory elements for glucocorticoid receptor (GR) and HNF4α were also identified in the CYP2C8 promoter.\",\n      \"method\": \"Reporter assays, gel shift assays, primary human hepatocyte induction studies\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter mapping with functional validation in primary hepatocytes; single study\",\n      \"pmids\": [\"15933212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"IL-1β inhibits CAR (NR1I3) expression and CAR-mediated induction of drug-metabolizing genes (CYP2B6, CYP2C9, CYP3A4, UGT1A1, GSTA1, GSTA2, SLC21A6) in human hepatocytes via NF-κB p65 activation, which interferes with glucocorticoid receptor (GR)-mediated transactivation of the CAR promoter through its distal glucocorticoid response element; LPS and IL-1β inhibit dexamethasone-induced histone H4 acetylation at the proximal CAR promoter region, as shown by chromatin immunoprecipitation.\",\n      \"method\": \"Human hepatocyte culture, RT-PCR, transient transfection assays, chromatin immunoprecipitation (ChIP), NF-κB inhibitor and overexpression studies\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP plus multiple functional assays demonstrating inflammatory suppression of CAR via NF-κB/GRE chromatin mechanism\",\n      \"pmids\": [\"15382119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CAR (NR1I3) regulates serum triglyceride levels under metabolic stress; ob/ob mice crossed onto Car−/− background show completely normalized serum triglycerides, and Car−/− mice are protected from high-fat diet-induced hypertriglyceridemia. Pharmacological CAR activation with TCPOBOP increases serum triglycerides in a CAR-dependent manner. CAR activation suppresses PPARα expression and its target genes (Cyp4a14, CPT1α, CTE), and Car−/− animals exhibit increased hepatic fatty acid oxidation, indicating that CAR antagonizes PPARα-mediated fatty acid oxidation.\",\n      \"method\": \"Car knockout and ob/ob mouse genetic crosses, high-fat diet model, pharmacological CAR activation (TCPOBOP), PPARα target gene expression analysis, fatty acid oxidation assays\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic mouse models with pharmacological validation; identifies PPARα as downstream effector\",\n      \"pmids\": [\"18941143\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CAR (NR1I3) and PXR cross-talk with multiple hormone-responsive transcription factors (FoxO1, FoxA2, CREB, PGC-1α) to downregulate hepatic energy metabolism including gluconeogenesis, fatty acid oxidation, and ketogenesis while upregulating lipogenesis; CAR also modulates thyroid hormone activity by regulating type 1 deiodinase in the regenerating liver.\",\n      \"method\": \"Gene expression studies, nuclear receptor cross-talk assays, hepatic metabolic pathway analysis in rodent models\",\n      \"journal\": \"Drug metabolism and pharmacokinetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — review synthesizing primary data; cross-talk mechanisms identified in multiple primary studies but summarized here\",\n      \"pmids\": [\"18305370\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Retinoids (including all-trans retinoic acid and 9-cis retinoic acid) activate the RXRα/CAR (NR1I3)-mediated pathway and induce CYP3A gene expression; RXRα and CAR are recruited to both the proximal ER6 and distal XREM nuclear receptor response elements of the CYP3A4 gene promoter, as demonstrated by chromatin immunoprecipitation assay. Induction is preferentially mediated by RXRα/CAR and RXRγ/CAR heterodimers.\",\n      \"method\": \"Transient transfection assays in HepG2 cells, chromatin immunoprecipitation (ChIP), RT-PCR\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP with functional reporter assays; single lab study\",\n      \"pmids\": [\"19686701\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"NR1I3 gene polymorphisms are significantly associated with tacrolimus pharmacokinetics (dose-adjusted trough concentration) in liver transplant patients, indicating that NR1I3 variants influence tacrolimus metabolism in vivo in humans.\",\n      \"method\": \"Pharmacokinetic analysis in 96 liver transplant patients, genotyping of NR1I3 and CYP3A5 polymorphisms, multiple linear regression modeling\",\n      \"journal\": \"Drug metabolism and pharmacokinetics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3-4 — clinical association study; no direct mechanistic experiment linking specific NR1I3 variant to altered gene expression or enzyme activity\",\n      \"pmids\": [\"24351870\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CAR (NR1I3) can be activated by both direct ligand binding and ligand-independent (indirect) mechanisms; without activation, CAR forms a cytoplasmic protein complex. Indirect activation involves nuclear translocation through multiple signaling pathways including those affecting the cytoplasmic retention complex, while direct activation involves ligand binding followed by nuclear translocation. Both modes of activation converge on nuclear accumulation and target gene transactivation.\",\n      \"method\": \"Review synthesizing protein complex studies, nuclear translocation assays, signaling pathway inhibitor studies\",\n      \"journal\": \"Protein & cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — review article synthesizing primary data from multiple labs on CAR signaling regulation\",\n      \"pmids\": [\"24474196\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Genome-wide characterization of CAR (NR1I3) binding in mouse liver after drug activation shows that CAR-linked genes are either stimulated or inhibited; stimulation but not inhibition correlates with increased H4K5 acetylation. Transcriptional inhibition occurs when CAR binds together with HNF4α, PPARα, or FXR on the same enhancers, where functional competition among co-bound nuclear receptors regulates metabolic gene expression. Drug-activated CAR displaces these endogenous metabolic regulators, constitutively altering metabolic gene regulation.\",\n      \"method\": \"ChIP-seq for CAR, RXRα, and H4K5Ac genome-wide in mouse liver; gene expression analysis\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — genome-wide ChIP-seq with integrated transcriptomics; mechanistically identifies competitive binding with HNF4α, PPARα, FXR at shared enhancers\",\n      \"pmids\": [\"30396153\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In human liver cancer, CAR (NR1I3) plays a tumor-suppressive role distinct from its pro-tumorigenic role in rodent models; CAR drives differentiation and liver regeneration and regulates liver cancer stem cells in human hepatocytes. Species differences in CAR activity mean that the rodent liver tumorigenesis mechanism is not applicable to humans.\",\n      \"method\": \"Review of human hepatocyte studies, liver cancer models; primary CAR activation/loss-of-function experiments in human liver cancer cells\",\n      \"journal\": \"Biochimica et biophysica acta. Reviews on cancer\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — review article; underlying primary mechanistic data not detailed in abstract\",\n      \"pmids\": [\"33529650\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NR1I3 (CAR) is a liver-enriched orphan nuclear receptor that forms a constitutively active heterodimer with RXRα, maintained in the active conformation by a unique Helix X that stabilizes the AF2 helix; it is held in a cytoplasmic protein complex until activated by direct ligand binding or indirect (ligand-independent) signaling-mediated nuclear translocation, whereupon it transactivates target genes (CYP2B6, CYP3A4, CYP2C8, CYP2C9, UGT1A1, and bilirubin-clearance genes) by binding DR-5/ER-6 response elements as an RXRα heterodimer and recruiting coactivators, while also inhibiting PPARα/HNF4α/FXR-dependent metabolic gene programs through competitive co-occupancy of shared enhancers, with its activity suppressed by endogenous androstane inverse agonists and by IL-1β/NF-κB-mediated chromatin remodeling at the CAR promoter.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"NR1I3 (CAR) is a liver-enriched nuclear receptor that functions as both a xenobiotic sensor and a metabolic regulator, coupling chemical exposure and endogenous metabolic signals to transcriptional programs governing drug detoxification, lipid homeostasis, glucose metabolism, and hepatocyte differentiation. In its inactive state CAR resides in a cytoplasmic protein complex; upon activation by direct ligand binding (e.g., CITCO) or ligand-independent signaling pathways, it translocates to the nucleus, heterodimerizes with RXRα, and binds DR-4, ER6, and XREM response elements to transactivate target genes including CYP2B6 and CYP3A4, with coactivator recruitment (SRC-1) dependent on intact AF-2 motifs on both CAR and RXR [PMID:16099843, PMID:19686701, PMID:24474196]. Genome-wide binding studies show that drug-activated CAR induces H4K5 acetylation at its target loci and functionally competes with HNF4α, PPARα, and FXR on shared enhancers, thereby suppressing fatty acid oxidation genes and elevating serum triglycerides under metabolic stress [PMID:30396153, PMID:18941143]. CAR also promotes hepatocyte differentiation and exhibits a tumor-suppressive role in human liver cancer, with notable species differences between rodent and human CAR activity [PMID:33529650].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Establishing CAR as a xenobiotic sensor resolved the question of how the liver coordinates induction of cytochrome P450 enzymes in response to diverse chemical exposures, positioning NR1I3 alongside PXR as a key transcriptional mediator of oxidative drug metabolism.\",\n      \"evidence\": \"Gene expression and reporter assays across multiple xenobiotic exposure models\",\n      \"pmids\": [\"12120277\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Precise ligand-binding specificity of CAR versus PXR not fully delineated\",\n        \"Mechanism of constitutive activity versus ligand-induced activation unclear\"\n      ]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Structural and functional comparison of CAR and PXR clarified that despite overlapping target genes, these xenosensors differ in ligand-binding domain architecture and activation mode, establishing a structural basis for their distinct pharmacological profiles.\",\n      \"evidence\": \"Crystallography/structural modeling combined with cell-based ligand profiling\",\n      \"pmids\": [\"12573482\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Full-length CAR structure not resolved\",\n        \"Structural basis for constitutive activity not determined\"\n      ]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Characterization of the CAR3 splice variant demonstrated that a 5-amino-acid insertion in the LBD converts CAR from constitutively active to strictly ligand-dependent, revealing the AF-2/RXRα/SRC-1 axis as the core transactivation mechanism on DR-4 and CYP2B6/CYP3A4 enhancers.\",\n      \"evidence\": \"Site-directed mutagenesis, reporter assays, mammalian two-hybrid assay for coactivator recruitment\",\n      \"pmids\": [\"16099843\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"In vivo relevance of CAR3 splice variant not tested\",\n        \"Additional coactivators or corepressors not surveyed\"\n      ]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Genetic and pharmacological studies in mice established CAR as a direct regulator of serum triglyceride levels, demonstrating that CAR activation suppresses PPARα target genes (Cyp4a14, CPT1α) to reduce hepatic fatty acid β-oxidation — revealing a metabolic role beyond xenobiotic detoxification.\",\n      \"evidence\": \"Car−/− mice on ob/ob and high-fat diet backgrounds, TCPOBOP pharmacological activation, gene expression analysis\",\n      \"pmids\": [\"18941143\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Direct versus indirect mechanism of PPARα suppression not resolved\",\n        \"Relevance of these lipid effects to human CAR activation not confirmed\"\n      ]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"ChIP experiments showed that retinoid-activated RXRα/CAR heterodimers are directly recruited to both ER6 and XREM elements of the CYP3A4 promoter, demonstrating that RXR ligands can drive CAR-mediated transcription on endogenous chromatin.\",\n      \"evidence\": \"Chromatin immunoprecipitation and luciferase reporter assays in cell lines\",\n      \"pmids\": [\"19686701\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single-lab finding; independent replication not reported\",\n        \"Physiological retinoid concentrations needed for in vivo relevance not defined\"\n      ]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Multiple studies converged on a two-mode activation model: CAR can be activated by direct ligand binding or by ligand-independent signaling pathways that trigger its nuclear translocation from a cytoplasmic retention complex, establishing phosphorylation-dependent regulation as a key control mechanism.\",\n      \"evidence\": \"Synthesis of protein complex studies, phosphorylation experiments, and nuclear translocation assays from multiple labs\",\n      \"pmids\": [\"23729557\", \"24474196\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Identity and stoichiometry of all cytoplasmic retention complex components not fully defined\",\n        \"Specific kinase/phosphatase cascades governing indirect activation incompletely mapped\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Genome-wide ChIP-seq provided a comprehensive map of CAR–RXRα binding across the mouse liver genome, showing that drug-activated CAR induces H4K5 acetylation at bound loci and competes with HNF4α, PPARα, and FXR on shared enhancers — establishing enhancer competition as the mechanism by which CAR reprograms metabolic gene expression.\",\n      \"evidence\": \"ChIP-seq for CAR and RXRα, H4K5Ac profiling, gene expression analysis in TCPOBOP-treated mouse liver\",\n      \"pmids\": [\"30396153\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether enhancer competition involves direct physical displacement or cofactor redistribution is unresolved\",\n        \"Human genome-wide CAR binding map not yet generated\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Functional cellular studies demonstrated that CAR promotes hepatocyte differentiation and acts as a tumor suppressor in human liver cancer, expanding its role beyond metabolism to cell fate determination — while highlighting critical species differences that limit rodent-to-human extrapolation.\",\n      \"evidence\": \"Loss-of-function and gain-of-function assays in human hepatocytes and cancer stem cell analyses\",\n      \"pmids\": [\"33529650\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Molecular targets mediating tumor-suppressive activity in human hepatocytes not identified\",\n        \"In vivo human evidence for tumor suppression lacking\",\n        \"Species-specific cofactor interactions not characterized\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Major unresolved questions include the full composition of the CAR cytoplasmic retention complex, the identity of kinases and phosphatases that mediate indirect activation in human hepatocytes, the genome-wide binding landscape of human CAR, and the molecular mechanism underlying CAR's tumor-suppressive function in human liver.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Human genome-wide CAR cistrome not established\",\n        \"Cytoplasmic retention complex components not fully characterized\",\n        \"Tumor-suppressive mechanism in human liver molecularly undefined\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 2, 9]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [2, 4, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [2, 4, 6, 8, 9]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [6, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 2, 4, 9]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [3, 5, 9, 11]},\n      {\"term_id\": \"R-HSA-9748784\", \"supporting_discovery_ids\": [0, 7]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"RXRA\",\n      \"HNF4A\",\n      \"PPARA\",\n      \"FXR\",\n      \"SRC-1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"NR1I3 (CAR) is a liver-enriched nuclear receptor that functions as a master xenobiotic sensor and transcriptional regulator of hepatic drug metabolism, bilirubin clearance, and energy homeostasis. It heterodimerizes with RXRα and binds DR-5 and ER-6 response elements on target gene promoters (CYP2B6, CYP3A4, CYP2C8, CYP2C9, UGT1A1) with constitutive transcriptional activity conferred by a unique Helix X that locks the AF-2 activation domain in an active conformation, enabling ligand-independent coactivator recruitment; endogenous androstane metabolites act as inverse agonists by promoting coactivator release [PMID:9783588, PMID:15610735]. CAR resides in a cytoplasmic retention complex and translocates to the nucleus upon direct agonist binding (e.g., CITCO) or indirect signal-mediated activation, where it induces phase I/II detoxification enzymes and bilirubin-clearance genes, while suppressing PPARα-, HNF4α-, and FXR-dependent metabolic programs through competitive co-occupancy of shared enhancers [PMID:12611900, PMID:12644704, PMID:30396153]. Chronic CAR activation in rodent liver promotes hepatocarcinogenesis through Mdm2 upregulation and p53 suppression, whereas inflammatory cytokines (IL-1β) suppress CAR transcription via NF-κB-mediated chromatin remodeling at its promoter [PMID:15831521, PMID:15382119].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"The initial cloning of NR1I3 (MB67) established it as a liver-enriched orphan nuclear receptor that heterodimerizes with RXR and exhibits constitutive (ligand-independent) transactivation on DR-5 elements, posing the question of how a nuclear receptor could be active without a known ligand.\",\n      \"evidence\": \"Receptor cloning, gel shift assays, and reporter assays in transfected cells\",\n      \"pmids\": [\"8114692\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No endogenous ligand identified\", \"Mechanism of constitutive activity unknown\", \"In vivo target genes undetermined\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"The mystery of constitutive activity was resolved by showing that CAR recruits coactivators without ligand, while androstanol and androstenol function as inverse agonists that release coactivators, defining a novel regulatory paradigm for nuclear receptors.\",\n      \"evidence\": \"In vitro coactivator interaction assays with stereospecific androstane structure-activity analysis\",\n      \"pmids\": [\"9783588\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for constitutive coactivator docking unknown\", \"Physiological relevance of androstane inverse agonism in vivo unconfirmed\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstration that CAR and PXR cross-regulate each other's target CYP genes through shared response elements established the concept of an overlapping xenobiotic sensor network rather than a one-receptor-one-target model.\",\n      \"evidence\": \"Reporter assays and transgenic mouse studies across CYP2B and CYP3A promoters\",\n      \"pmids\": [\"11114890\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide extent of overlap not mapped\", \"Mechanisms determining preferential receptor usage at shared elements unclear\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Genetic loss-of-function studies using CAR-null mice proved that CAR is required for acetaminophen hepatotoxicity and mapped specific CAR-dependent CYP target genes essential for acetaminophen bioactivation, linking CAR activity directly to drug toxicity outcomes.\",\n      \"evidence\": \"CAR knockout mice challenged with acetaminophen; pharmacological rescue with androstanol inverse agonist\",\n      \"pmids\": [\"12376703\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Human relevance of CAR-dependent acetaminophen toxicity not directly tested\", \"Full spectrum of CAR-regulated acetaminophen-metabolizing enzymes not enumerated\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"CAR was shown to coordinate the entire bilirubin-clearance pathway (uptake, conjugation, excretion), with bilirubin itself acting as a direct CAR activator; low neonatal CAR expression was linked to neonatal jaundice susceptibility, establishing CAR's role in endobiotic homeostasis beyond xenobiotic sensing.\",\n      \"evidence\": \"CAR knockout and humanized CAR mouse models with bilirubin clearance assays and receptor activation studies\",\n      \"pmids\": [\"12644704\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct structural evidence for bilirubin binding to CAR LBD absent\", \"Contribution of CAR variants to clinical neonatal jaundice not tested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identification of CITCO as the first selective human CAR agonist provided a critical pharmacological tool, enabling distinction of CAR- vs PXR-mediated gene regulation and confirming CYP2B6 as a prototypical CAR target gene.\",\n      \"evidence\": \"Fluorescence-based receptor activation, nuclear translocation assay, and primary human hepatocyte gene expression profiling\",\n      \"pmids\": [\"12611900\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CITCO selectivity in vivo at physiological doses not fully established\", \"Structural basis for CITCO selectivity over PXR unknown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"The crystal structure of the CAR/RXRα heterodimer revealed a unique single-turn Helix X that restricts AF-2 conformational freedom, providing the structural explanation for constitutive coactivator recruitment and answering the long-standing question of how CAR achieves ligand-independent activity.\",\n      \"evidence\": \"X-ray crystallography of the human CAR/RXRα heterodimer complex\",\n      \"pmids\": [\"15610735\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of CAR bound to inverse agonist not resolved\", \"Dynamics of Helix X upon androstanol binding not captured\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"IL-1β/NF-κB was found to suppress CAR expression via interference with GR-mediated CAR promoter transactivation and chromatin remodeling (reduced H4 acetylation), providing a molecular mechanism for inflammation-mediated downregulation of drug metabolism.\",\n      \"evidence\": \"ChIP, reporter assays, NF-κB overexpression/inhibitor studies in human hepatocytes\",\n      \"pmids\": [\"15382119\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Contribution of additional inflammatory cytokines to CAR suppression not systematically studied\", \"In vivo chromatin remodeling at the CAR locus during inflammation not confirmed\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Chronic CAR activation was shown to cause hepatocarcinogenesis in mice through direct upregulation of Mdm2 and suppression of p53-mediated apoptosis, identifying a specific oncogenic mechanism and distinguishing acute protective xenobiotic responses from chronic tumorigenic risk.\",\n      \"evidence\": \"CAR knockout mouse carcinogenesis models with Mdm2 expression analysis and apoptosis/DNA replication assays\",\n      \"pmids\": [\"15831521\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Human relevance disputed — evidence suggests tumor-suppressive role of CAR in human liver\", \"Direct CAR binding to the Mdm2 promoter not confirmed by ChIP\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"CAR was established as a metabolic regulator beyond drug metabolism: its activation suppresses PPARα expression and fatty acid oxidation genes, increasing serum triglycerides, while CAR deletion normalizes hypertriglyceridemia in obese mice.\",\n      \"evidence\": \"Car knockout crossed with ob/ob mice, high-fat diet model, TCPOBOP activation, PPARα target gene and fatty acid oxidation assays\",\n      \"pmids\": [\"18941143\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CAR directly binds PPARα regulatory elements or acts indirectly unknown\", \"Human metabolic relevance of CAR-PPARα antagonism not established\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Genome-wide ChIP-seq in mouse liver revealed that CAR stimulates target genes with increased H4K5 acetylation but inhibits metabolic genes by co-binding enhancers occupied by HNF4α, PPARα, and FXR, establishing competitive enhancer co-occupancy as the mechanism for CAR-mediated metabolic reprogramming.\",\n      \"evidence\": \"ChIP-seq for CAR, RXRα, and H4K5Ac genome-wide in drug-activated mouse liver integrated with transcriptomics\",\n      \"pmids\": [\"30396153\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Human liver ChIP-seq for CAR not performed\", \"Coactivator/corepressor dynamics at competitively bound enhancers not resolved\", \"Single-cell heterogeneity of CAR-bound enhancer states not addressed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of inverse agonist-induced conformational change, the identity and regulation of the cytoplasmic CAR retention complex components, species-specific differences in CAR's role in liver tumorigenesis versus tumor suppression, and the genome-wide CAR cistrome in human liver.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No inverse agonist-bound CAR crystal structure\", \"Cytoplasmic retention complex composition incompletely defined\", \"Human hepatic CAR ChIP-seq data lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 2, 5, 7, 8, 13, 22]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 1, 5, 6, 12, 22]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [2, 17, 22]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [7, 11, 19, 21, 22]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [21]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0074160\", \"supporting_discovery_ids\": [0, 1, 5, 6, 7, 8, 13, 22]},\n      {\"term_id\": \"R-HSA-9748784\", \"supporting_discovery_ids\": [3, 4, 5, 6, 7, 8, 9, 15]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [8, 9, 17, 18, 22]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [16, 21, 22]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [14, 23]}\n    ],\n    \"complexes\": [\n      \"CAR/RXRα heterodimer\"\n    ],\n    \"partners\": [\n      \"RXRA\",\n      \"NR1I2\",\n      \"HNF4A\",\n      \"PPARA\",\n      \"NR1H4\",\n      \"SRC1\",\n      \"RELA\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}